膜细胞淋巴瘤:在过去5年中,临床进展如何?
Charbel Soueidy1, Jean-Marie Michot1,2,3, Vincent Ribrag1,2,3
1Département des Innovations Thérapeutiques et des Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.
Expert opinion on investigational drugs
|February 24, 2025
概括
布鲁顿激酶抑制剂正在改变地幔细胞淋巴瘤的治疗方法. 建议添加易布鲁替尼,并讨论了遗漏自身干细胞移植,使用CAR-T细胞治疗复发病例.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 仍然是一个重要的淋巴细胞恶性瘤,正在进行临床研究.
- 最近布鲁顿氨酸激酶 (BTK) 抑制剂的进展已经显著改变了患者的治疗策略.
研究的目的:
- 审查用于上衣细胞淋巴瘤 (MCL) 治疗的关键临床试验.
- 评估年轻和老年患者的前线和复发/耐药情形.
- 突出BTK抑制剂对结果和自身干细胞移植 (ASCT) 的影响.
主要方法:
- 对MCL治疗中关键临床试验的综述.
- 分析治疗策略,包括BTK抑制剂,ASCT和CAR-T细胞.
- 专注于患者群体:前线,复发/耐药,年轻人和老年人.
主要成果:
- 在TRIANGLE试验建议添加ibrutinib诱导和维护治疗的MCL.
- 遗漏自身干细胞移植 (ASCT) 需要对所有MCL患者进行仔细考虑.
- 最小残留性疾病 (MRD) 正成为维持治疗决策的关键生物标志物.
结论:
- 最近的数据强烈支持将易布鲁替尼纳入MCL治疗方案.
- 在MCL治疗中ASCT的作用和必要性需要在新药时代重新评估.
- 化学抗原受体T细胞 (CAR-T) 治疗是BTK后复发性/耐火性MCL抑制的主要选择.
更多相关视频
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K


